• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Azenta Inc. (Amendment)

    11/1/23 4:02:04 PM ET
    $AZTA
    Industrial Machinery/Components
    Technology
    Get the next $AZTA alert in real time by email
    SC 13D/A 1 tm2329437d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Azenta, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

    114340102

    (CUSIP Number)

     

    Quentin Koffey

    Politan Capital Management LP

    106 West 56th Street, 10th Floor

    New York, New York 10019

    646-690-2830

     

    With a copy to:

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    212-504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    October 30, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,578,003

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,578,003

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,578,003

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.61%*

    14

    TYPE OF REPORTING PERSON

     

    IA

         

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2023. 

     

     

     

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,578,003

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,578,003

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,578,003

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.61%*

    14

    TYPE OF REPORTING PERSON

     

    IA

         

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Partners GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,578,003

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,578,003

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,578,003

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.61%*

    14

    TYPE OF REPORTING PERSON

     

    IA

         

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    1

    NAME OF REPORTING PERSON

    Quentin Koffey

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,578,003

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,578,003

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,578,003

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.61%*

    14

    TYPE OF REPORTING PERSON

     

    IN

         

    * All percentage calculations set forth herein are based upon the aggregate of 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

     

     

     

    This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) amends and supplements the Schedule 13D filed on September 14, 2023 (the “Initial 13D”, and as amended and supplemented by this Amendment No. 1, the “Schedule 13D”) by the Reporting Persons, relating to the common stock, par value $0.01 per share (the “Common Stock”), of Azenta, Inc., a Delaware corporation (the “Issuer”). Capitalized terms not defined in this Amendment No. 1 shall have the meaning ascribed to them in the Initial 13D.

     

    The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

     

    ITEM 1. SECURITY AND ISSUER

     

    Item 1 of the Schedule 13D is hereby amended and supplemented with the following information:

     

    Each of the Reporting Persons beneficially owns an aggregate of 4,578,003 shares of Common Stock. These shares represent approximately 7.61% of the outstanding shares of Common Stock.

     

    ITEM 4. PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is hereby amended and supplemented with the following information:

     

    Politan has entered into a non-disclosure agreement with the Issuer and is currently engaging in discussions with the Issuer’s management and board of directors (the “Board”) concerning the Issuer’s business, strategies and corporate governance. Coincident with these discussions, due to the November 2, 2023 nomination deadline in the Amended and Restated Bylaws of the Issuer (the “Bylaws”), on October 30, 2023, Politan Capital NY LLC, in compliance with the Bylaws, submitted to the Issuer its formal notice to nominate candidates for election to the Board, one of whom is Politan’s Managing Partner and Chief Investment Officer Quentin Koffey.

     

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5(a) and Item 5(b) of the Initial Schedule 13D are hereby amended and restated as follows:

     

    (a), (b) Each of the Reporting Persons beneficially owns an aggregate of 4,578,003 shares of Common Stock (the “Subject Shares”). The Subject Shares represent approximately 7.61% of the outstanding shares of Common Stock, based on 60,153,892 shares of Common Stock outstanding as of August 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2023.

     

    Politan, as the investment advisor to the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares. Politan Management, as the general partner of Politan, which is in turn the investment advisor to the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares. Politan GP, as the general partner of the Politan Funds, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares. Mr. Koffey, as the Managing Partner And Chief Investment Officer of Politan, and as the Managing Member of Politan Management and Politan GP, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares.

     

    Item 5(c) of the Initial Schedule 13D is hereby amended and supplemented by adding the following information:

     

    Exhibit 99.3 filed herewith, which is incorporated herein by reference, describes the transaction in Common Stock that was effected by the Reporting Persons for the benefit of the Politan Funds since the filing of the Initial 13D.

     

     

     

     

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

     

    Item 6 of the Initial Schedule 13D is hereby amended and supplemented by adding the following information:

     

    On September 18, 2023, Politan Master Fund exercised the Physically Settled Swaps referencing 728,415 shares of Common Stock and, upon such settlement, the counterparties to such Physically Settled Swaps delivered to Politan Master Fund an aggregate of 728,415 shares of Common Stock. Politan Master Fund had previously settled the Cash Settled Swaps in full under which it had economic exposure to 385,196 notional shares of Common Stock. Politan Master Fund is no longer a party to any Physically Settled Swaps or Cash Settled Swaps.

     

    The information set forth in Item 4 with respect to the non-disclosure agreement entered into by Politan and the Issuer is incorporated herein by reference.

     

    Except as described herein, the Reporting Persons have no contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer.

     

    ITEM 7. MATERIAL TO BE FILED AS AN EXHIBIT

     

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
       
    Exhibit 99.2 Trading Data*
       
    Exhibit 99.3 Trading Data

     

    *Previously filed.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 1, 2023

     

      POLITAN CAPITAL MANAGEMENT LP
         
      By: Politan Capital Management GP LLC,
    its general partner
         
      By: /s/ Quentin Koffey
        Name:    Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL MANAGEMENT GP LLC
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
         
      POLITAN CAPITAL PARTNERS GP LLC
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
         
      QUENTIN KOFFEY
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey

     

     

     

     

    INDEX TO EXHIBITS

     

    Exhibit   Description
         
    Exhibit 99.1   Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
         
    Exhibit 99.2   Trading Data*
         
    Exhibit 99.3   Trading Data

     

    *Previously filed.

     

     

     

    Get the next $AZTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTA

    DatePrice TargetRatingAnalyst
    12/18/2024$50.00 → $60.00Equal-Weight → Overweight
    Stephens
    4/4/2024$64.00Hold
    Jefferies
    2/1/2024$61.00 → $79.00Buy
    B. Riley Securities
    7/19/2023Mkt Perform
    Raymond James
    5/10/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    2/9/2023$65.00 → $60.00Overweight → Equal-Weight
    Stephens
    1/3/2023$60.00 → $62.00Outperform → In-line
    Evercore ISI
    3/31/2022$106.00Buy
    B. Riley Securities
    More analyst ratings

    $AZTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report

      BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental Protection: We understand the broad impact of our operations and the potential to impact the world. We are committed to evaluating ways to reduce our environmental footprint while continu

      3/24/25 4:05:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Azenta upgraded by Stephens with a new price target

      Stephens upgraded Azenta from Equal-Weight to Overweight and set a new price target of $60.00 from $50.00 previously

      12/18/24 7:25:24 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Jefferies initiated coverage on Azenta with a new price target

      Jefferies initiated coverage of Azenta with a rating of Hold and set a new price target of $64.00

      4/4/24 7:29:19 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • B. Riley Securities reiterated coverage on Azenta with a new price target

      B. Riley Securities reiterated coverage of Azenta with a rating of Buy and set a new price target of $79.00 from $61.00 previously

      2/1/24 8:17:35 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Azenta Inc.

      10-Q - Azenta, Inc. (0000933974) (Filer)

      5/9/25 4:07:49 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      5/7/25 7:05:31 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Azenta, Inc. (0000933974) (Filer)

      4/9/25 4:30:57 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azenta Inc.

      SC 13G/A - Azenta, Inc. (0000933974) (Subject)

      11/13/24 4:05:02 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Amendment: SEC Form SC 13D/A filed by Azenta Inc.

      SC 13D/A - Azenta, Inc. (0000933974) (Subject)

      11/4/24 8:41:47 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • SEC Form SC 13G filed by Azenta Inc.

      SC 13G - Azenta, Inc. (0000933974) (Subject)

      10/31/24 11:55:02 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Manager, Genom Zhou Ginger bought $19,132 worth of Common (417 units at $45.88), increasing direct ownership by 2% to 27,916 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/4/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • President and CEO Marotta John was granted 83,622 units of Common and bought $552,904 worth of Common (13,967 units at $39.59), increasing direct ownership by 2,982% to 100,862 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:16 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Cornog William L bought $495,000 worth of Common (12,500 units at $39.60) (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      11/19/24 4:10:11 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

      NEW YORK, Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE:ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. Azenta's market capitalization is no longer representative of the mid-cap market space.Concentra Group Holdings Inc. (NYSE:CON) will replace Myers Industries Inc. (NYSE:MYE) in the S&P SmallCap 600 effective prior to the openin

      11/19/24 5:56:00 PM ET
      $AZTA
      $CON
      $ENV
      $FLEX
      Industrial Machinery/Components
      Technology
      Medical Specialities
      Health Care
    • Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

      William L. Cornog, Quentin Koffey and Alan J. Malus Add Deep Industry Expertise and Track Records of Shareholder Value Creation to the Board Establishes Value Creation Committee of the Board Comprised of New Directors, CEO John Marotta, and Current Director Martin Madaus Reaffirms Full-Year 2024 Financial Guidance BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced the appointment of three new independent directors to its Board. William Cornog, former head of KKR Capstone, the portfolio operations team of KKR & Co., and Alan Malus, former Corporate Executive Vice President of Thermo Fisher, join as part of Azenta's ongoing i

      11/4/24 8:00:00 AM ET
      $AZTA
      $BV
      $LVWR
      Industrial Machinery/Components
      Technology
      Business Services
      Consumer Discretionary
    • AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO

      Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition.  Mr. Marotta has two decades of experience leading global companies in life sciences, medical devices, and diagnostics, and is joining Azenta from Patient Square Capital, a leading healthcare investment firm, where he serves as Executive in Residence. P

      9/4/24 8:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO and Treasurer Lin Lawrence Y. was granted 2,200 units of Common, increasing direct ownership by 6% to 37,513 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/13/25 4:10:05 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Koffey Quentin was granted 4,040 shares, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:48:51 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Director Malus Alan J was granted 4,040 units of Common, increasing direct ownership by 406% to 5,035 units (SEC Form 4)

      4 - Azenta, Inc. (0000933974) (Issuer)

      2/11/25 4:10:12 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology

    $AZTA
    Financials

    Live finance-specific insights

    See more
    • Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

      BURLINGTON, Mass., May 7, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operat

      5/7/25 6:30:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast

      BURLINGTON, Mass., April 24, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, May 7, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on May 8, 2025. About Azenta Life Sciences Azenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling impac

      4/24/25 4:15:00 PM ET
      $AZTA
      Industrial Machinery/Components
      Technology
    • Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

      BURLINGTON, Mass., Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2024. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the fourth fiscal quarter of 2024 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data December 31, September 30, December 31, Change 2024 2024 2023 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 148 $ 151 $ 142 (2) % 4 % Organic growth 4 % Sample Management Solutions $ 81 $ 85 $ 79 (4) % 3 % Multiomics $ 66 $ 66 $ 63 0 % 6 % Diluted EPS Continui

      2/5/25 7:00:00 AM ET
      $AZTA
      Industrial Machinery/Components
      Technology